Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to evaluate the interest of a six month pre-operative treatment with a long-acting somatostatin analog (Sandostatin LP) versus surgery alone in patients with a pituitary adenoma responsible for acromegaly.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Rouen
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• men and women

• 18-80 years old

• untreated acromegaly

• unsuppressed GH secretion after a glucose load and elevated IGF-1 plasma levels

• presence of a pituitary adenoma on MRI

• informed consent given.

Exclusion Criteria:

• acromegaly previously treated

• contraindication to pituitary surgery

• associated hyperprolactinemia above 200 ng/ml

• visual field defect needing rapid transsphenoidal surgery

• contraindication to a treatment with octreotide